当前位置: 首页 >> 检索结果
1801. Genomic and transcriptomic profiling of carcinogenesis in patients with familial adenomatous polyposis.
作者: Jingyun Li.;Rui Wang.;Xin Zhou.;Wendong Wang.;Shuai Gao.;Yunuo Mao.;Xinglong Wu.;Limei Guo.;Haijing Liu.;Lu Wen.;Wei Fu.;Fuchou Tang.
来源: Gut. 2020年69卷7期1283-1293页
Familial adenomatous polyposis (FAP) is characterised by the development of hundreds to thousands of adenomas at different evolutionary stages in the colon and rectum that will inevitably progress to adenocarcinomas if left untreated. Here, we investigated the genetic alterations and transcriptomic transitions from precancerous adenoma to carcinoma.
1803. Hepatitis E virus replication in human intestinal cells.
作者: Olivier Marion.;Sebastien Lhomme.;Manon Nayrac.;Martine Dubois.;Mélanie Pucelle.;Mary Requena.;Marion Migueres.;Florence Abravanel.;Jean Marie Peron.;Nicolas Carrere.;Bertrand Suc.;Pierre Delobel.;Nassim Kamar.;Jacques Izopet.
来源: Gut. 2020年69卷5期901-910页
Hepatitis E virus (HEV), one of the most common agent of acute hepatitis worldwide, is mainly transmitted enterically, via contaminated water for HEV genotypes 1 (HEV1) and HEV2, or by eating raw or undercooked infected meat for HEV genotype 3 (HEV3) and HEV4. However, little is known about how the ingested HEV reaches the liver or its ability to replicate in intestinal cells.
1804. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
作者: Wen-Ping Xu.;Jin-Pei Liu.;Ji-Feng Feng.;Chang-Peng Zhu.;Yuan Yang.;Wei-Ping Zhou.;Jin Ding.;Chen-Kai Huang.;Ya-Lu Cui.;Chen-Hong Ding.;Xin Zhang.;Bin Lu.;Wei-Fen Xie.
来源: Gut. 2020年69卷7期1309-1321页
Autophagy participates in the progression of hepatocellular carcinoma (HCC) and the resistance of HCC cells to sorafenib. We investigated the feasibility of sensitising HCC cells to sorafenib by modulating miR-541-initiated microRNA-autophagy axis.
1807. Endoscopic mucosal resection is effective for laterally spreading lesions at the anorectal junction.
作者: Neal Shahidi.;Mayenaaz Sidhu.;Sergei Vosko.;W Arnout van Hattem.;Iddo Bar-Yishay.;Scott Schoeman.;David J Tate.;Bronte Holt.;Luke F Hourigan.;Eric Yt Lee.;Nicholas G Burgess.;Michael J Bourke.
来源: Gut. 2020年69卷4期673-680页
The optimal approach for removing large laterally spreading lesions at the anorectal junction (ARJ-LSLs) is unknown. Endoscopic mucosal resection (EMR) is a definitive therapy for colorectal LSLs. It is unclear whether it is an effective modality for ARJ-LSLs.
1809. STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis.
作者: Christina Heichler.;Kristina Scheibe.;Anabel Schmied.;Carol I Geppert.;Benjamin Schmid.;Stefan Wirtz.;Oana-Maria Thoma.;Viktoria Kramer.;Maximilian J Waldner.;Christian Büttner.;Henner F Farin.;Marina Pešić.;Ferdinand Knieling.;Susanne Merkel.;Anika Grüneboom.;Matthias Gunzer.;Robert Grützmann.;Stefan Rose-John.;Sergei B Koralov.;George Kollias.;Michael Vieth.;Arndt Hartmann.;Florian R Greten.;Markus F Neurath.;Clemens Neufert.
来源: Gut. 2020年69卷7期1269-1282页
Cancer-associated fibroblasts (CAFs) influence the tumour microenvironment and tumour growth. However, the role of CAFs in colorectal cancer (CRC) development is incompletely understood.
1810. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
作者: Michael Goggins.;Kasper Alexander Overbeek.;Randall Brand.;Sapna Syngal.;Marco Del Chiaro.;Detlef K Bartsch.;Claudio Bassi.;Alfredo Carrato.;James Farrell.;Elliot K Fishman.;Paul Fockens.;Thomas M Gress.;Jeanin E van Hooft.;R H Hruban.;Fay Kastrinos.;Allison Klein.;Anne Marie Lennon.;Aimee Lucas.;Walter Park.;Anil Rustgi.;Diane Simeone.;Elena Stoffel.;Hans F A Vasen.;Djuna L Cahen.;Marcia Irene Canto.;Marco Bruno.; .
来源: Gut. 2020年69卷1期7-17页
The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals).
1811. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
作者: Sung Won Lee.;Jung Hyun Kwon.;Hae Lim Lee.;Sun Hong Yoo.;Hee Chul Nam.;Pil Soo Sung.;Soon Woo Nam.;Si Hyun Bae.;Jong Young Choi.;Seung Kew Yoon.;Nam Ik Han.;Jeong Won Jang.
来源: Gut. 2020年69卷7期1301-1308页
The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver-related events. However, whether there is a difference between the two agents in the extent of improving such outcomes has not been clarified thus far. Therefore, we aimed to compare TDF and ETV on the risk of HCC and mortality.
1812. Putative function of goblet cells as epithelial sealing in ischaemia/reperfusion-induced intestinal barrier dysfunction.
作者: Yuk Lung Wong.;Lars Hummitzsch.;Ingmar Lautenschläger.;Karina Zitta.;Thilo Wedel.;François Cossais.;Clemens Schafmayer.;Thomas Becker.;Rouven Berndt.;Matthias Gruenewald.;Norbert Weiler.;Markus Steinfath.;Martin Albrecht.
来源: Gut. 2020年69卷10期1888-1890页 1813. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species.
作者: Malte Christoph Rühlemann.;Miriam Emmy Leni Solovjeva.;Roman Zenouzi.;Timur Liwinski.;Martin Kummen.;Wolfgang Lieb.;Johannes Roksund Hov.;Christoph Schramm.;Andre Franke.;Corinna Bang.
来源: Gut. 2020年69卷10期1890-1892页 1818. New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection.
作者: Cesare Hassan.;Michael B Wallace.;Prateek Sharma.;Roberta Maselli.;Vincenzo Craviotto.;Marco Spadaccini.;Alessandro Repici.
来源: Gut. 2020年69卷5期799-800页 1820. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
作者: Chen Liang.;Si Shi.;Yi Qin.;Qingcai Meng.;Jie Hua.;Qiangshen Hu.;Shunrong Ji.;Bo Zhang.;Jin Xu.;Xian-Jun Yu.
来源: Gut. 2020年69卷5期888-900页
Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive type of GI tumour, and it possesses deregulated cellular energetics. Although recent advances in PDAC biology have led to the discovery of recurrent genetic mutations in Kras, TP53 and SMAD4, which are related to this disease, clinical application of the molecular phenotype of PDAC remains challenging.
|